Presenter Disclosure Information
|
|
- Shanon Earl Lamb
- 5 years ago
- Views:
Transcription
1 1:45 2:45pm Lipid Management: A Primary Care Perspective Presenter Disclosure Information The following relationships exist related to this presentation: Richard F. Wright, MD, FACC, has no financial relationships to disclose. SPEAKER Richard F. Wright, MD, FACC Off-Label/Investigational Discussion In accordance with pmicme policy, faculty have been asked to disclose discussion of unlabeled or unapproved use(s) of drugs or devices during the course of their presentations. Learning Objectives Utilize evidence-based lipoprotein management strategies for non-ldl-c lipid targets Describe the risk factors, disease spectrum, and appropriate management of familial hypercholesterolemia 213 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce ASCVD in Adults Four statin benefit groups: 1. Patients with CVD (ACS, MI, angina, revascularization, stroke, TIA, PVD) but w/o class II-IV CHF (with LVEF<35%) or ESRD 2. LDL-C > 19 mg/dl 3. Patients age 4-75 with diabetes and LDL-C 7-19 w/o CVD 4. Patients w/o CVD or diabetes, age 4-75 with LDL 7-19 mg/dl and a 1 yr risk 7.5% No evidence to support use of LDL-C or nonhdl-c treatment targets; instead use appropriate statin intensity Stone NJ, et al. 213 ACC/AHA Blood Cholesterol Guideline. J Am Coll Cardiol Nov ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce ASCVD in Adults High-intensity statins (lower LDL > 5%): Group 1 and 2 Atorvastatin 4-8 mg Rosuvastatin 2-4 mg Moderate-intensity statins (lower LDL 3-5%): Group 3 & 4 Atorvastatin 1-2 mg Pravastatin 4 mg Rosuvastatin 1 mg Lovastatin 4 mg Simvastatin 2-4 mg Non-statin lipid drugs alone or in combination with statins: no data to make any recommendation No recommendation about primary prevention in patients with 1 yr risk < 7.5%; use clinical judgment and other factors: FHx, LDL-C > 16 mg/dl, hs-crp > 2 mg/l, CACS > 3, ABI <,9 or high lifetime risk. Stone NJ, et al. 213 ACC/AHA Blood Cholesterol Guideline. J Am Coll Cardiol Nov 213 Non-HDL Cholesterol and CVD Risk Non-HDL-C Calculation: Non-HDL-C = TC-HDLC Non-HDL-C Goal: 3 mg/dl above LDL-C goal Significance of Non-HDL-C Encompasses all known and potential atherogenic lipid particles (linearly proportional to Apo B) Has been shown to be a stronger predictor of cardiovascular death than LDL-C, especially in women Bittner V. Curr Opin Lipidol. 23;14: Cui Y, et al. Arch Intern Med. 21;161: Ridker PM. JAMA. 25; 294: Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Circulation. 22;16:
2 LDL Particle Number Distribution in Type 2 Diabetes Subjects Percent of Subjects Percent of Subjects 5 th 2 th 5 th 8 th percentile 2 1% 24% 43% 21% 11% (n=19) (n=364) (n=631) (n=37) (n=163) (nmol/l) 2 16% 43% 3% 9% 2% (n=147) (n=377) (n=26) (n=76) (n=15) % Cromwell WC, Otvos JD. (nmol/l) AJC. 26;98: LDL-C 7-99 mg/dl (n=1,484) LDL-C < 7 mg/dl (n=871) History of Niacin Therapy for Raising HDL Coronary Drug Project (1975) men with previous MI and hypercholesterolemia Mean follow-up 6.2 years Total mortality similar in the two groups at 5 years (24.4% niacin vs 25.4% placebo, P=NS) Niacin did provide a significant reduction in recurrent nonfatal MI (27% reduction, P <.4) HDL-Atherosclerosis Treatment Study (HATS) (21) 2 3-year, randomized, double-blind trial 16 patients with coronary disease, low HDL-C, and normal LDL-C levels Simvastatin plus niacin resulted in significant regression of angiographic coronary atherosclerosis and reductions in clinical events rate 1. Coronary Drug Project. JAMA. 1975;231: Brown BG, et al. N Engl J Med. 21;345: AIM-HIGH: Niacin Plus Statin to Prevent Vascular Events ER niacin 5/1/15/2 mg and simvastatin 4 mg 4-8 week run-in with niacin dose increased each week Inclusion Criteria Age 45 History of vascular disease Atherogenic dyslipidemia LDL-C 16 mg/dl HDL-C 4 mg/dl men or 5 mg/dl women TG 15 mg/dl 4 mg/dl For patients entering the trial on a statin HDL-C 42 mg/dl men or 53 mg/dl women TG 125 mg/dl 4 mg/dl ER niacin 2 or 15 mg and simvastatin 2/4/8 mg* Simvastatin 2/4/8 mg* 3-5 years * dependent on LDL-C levels, ezetimibe 1 mg may be added Primary Endpoint Composite Endpoint for first event: CHD death nonfatal MI ischemic stroke hospitalization for high-risk non-stemi ACS Secondary Endpoint Composite of CHD death, nonfatal MI, or ischemic stroke out to common date AIM-HIGH Investigators. N Engl J Med. 211;365: AIM-HIGH Baseline Lipids (mg/dl) On Statin (n=3,196) Off Statin (n=218) LDL-C (mean) HDL-C (mean) Triglycerides (median) Non-HDL (mean) Apo-B (mean) AIM-HIGH Investigators. N Engl J Med. 211;365: AIM-HIGH Primary Outcome: First CV Event* AIM-HIGH: What Happened? Cumulative % with Primary Outcome Combination Therapy Monotherapy HR 1.2, 95% CI.87, 1,21 Log-rank P value=.79 Lipid Outcomes with Niacin: HDL-C from 35 to 42 mg/dl TG from 164 to 122 mg/dl LDL-C from 74 to 62 mg/dl 16.4% 16.2% ER niacin vs placebo + simvastatin/ezetimibe N at risk Time (years) *composite of death from CHD, nonfatal MI, ischemic stroke, hospitalization for ACS, or symptom-driven coronary or cerebral revascularization AIM-HIGH Investigators. N Engl J Med. 211;365: In this aggressively managed group of patients, was there no residual risk, hence no need for niacin? Prior studies done with Niacin IR. Perhaps niacin ER ineffective? effect? Niacin did not lower Apo B or LDL-P? Otvos JD. J Clin Lipidol. 211;5: HDL raising not effective if LDL-P or Apo B at goal? Perhaps raising HDL-C with no impact on HDL-P with low ApoB/LDL-P levels is not effective? The surprising AIM-HIGH results are not surprising when viewed through a particle lens (Otvos, 211)
3 HPS2-THRIVE Trial Randomized, placebo-controlled trial of ER niacin and laropiprant* 25,673 men and women with pre-existing cardiovascular disease Aged 5-8 years Prior history of: MI, ischaemic stroke or TIA, PAD, or diabetes with other CHD No contraindication to study treatments No significant liver, kidney or muscle disease * Laropiprant not FDA approved; suspended worldwide 213 HPS2-THRIVE Collaborative Group. Eur Heart J. 213;34: HPS2-THRIVE: Characteristics of Randomized Participants % or mean (SD) ERN/LRPT (12,838) (12,835) Men 83% 83% 21,229 (83%) Age (years) (7.5) Prior disease Coronary 78% 78% 2,137 (78%) Cerebrovascular 32% 32% 817 (32%) Peripheral arterial 13% 12% 3214 (13%) Diabetes 32% 32% 8299 (32%) HPS2-THRIVE Collaborative Group. Eur Heart J. 213;34: All ERN=extended release niacin LRPT=laropiprant HPS2-THRIVE: Baseline Lipids on Statin- Based Therapy Mean (SD) baseline mg/dl mmol/l Total cholesterol 128 (22) 3.32 (.57) Direct-LDL 63 (17) 1.64 (.44) HDL 44 (11) 1.14 (.29) Triglycerides* 125 (74) 1.43 (.84) *64% fasted for >8 hours HPS2-THRIVE Collaborative Group. Eur Heart J. 213;34: HPS2-THRIVE: Reasons for Stopping Study Treatment ERN/LRPT (12,838) (12,835) Excess Any medical 16.4% 7.9% 8.5% Skin 5.4% 1.2% 4.2% Gastrointestinal 3.9% 1.7% 2.1% Musculoskeletal 1.8% 1.%.8% Diabetes-related.9%.4%.5% Liver.4%.3%.1% Other 4.1% 3.3%.8% Any non-medical 8.9% 8.7%.3% Any reason 25.4% 16.6% 8.7% 78% average compliance with active ERN/LRPT HPS2-THRIVE Collaborative Group. Eur Heart J. 213;34: LRPT=laropiprant ERN=extended release niacin HPS2-THRIVE: Effect of ERN/LRPT on Serious Adverse Events Diabetic complication New onset diabetes Infection Gastrointestinal Musculoskeletal Heart failure Bleeding Skin Excess p value 3.7% <.1 1.8% <.1 1.4% <.1 1.% <.1 Active ERN/LRPT.7%.4%.8.5.7%.2 Median follow-up: 3.9 years.3% LRPT=laropiprant Percentage of patients ERN=extended release niacin HPS2-THRIVE Collaborative Group. Eur Heart J. 213;34: ERN/LRPT: GI, Muscle & Skin SAEs Serious Adverse Event Risk ratio (95% CI) ERN/LRPT (12,838) (12,835) Gastrointestinal GI bleeding.8%.6% 1.53 ( ) Peptic ulcer/upper GI 1.9% 1.4% 1.37 ( ) Lower GI.9%.7% 1.39 ( ) Other GI 1.% 1.%.99 ( ) Any gastrointestinal SAE 62 (4.8%) 491 (3.8%) 1.28 ( ) Musculoskeletal Myopathy.6%.1% 4.43 ( ) Gout.3%.2% 1.91 ( ) Other 2.9% 2.7% 1.8 ( ) Any musculoskeletal SAE 481 (3.7%) 385 (3.%) 1.26 ( ) Skin Rash.4%.3% 1.63 ( ) Ulcer.2%.1% 1.61 ( ) Other.1%.% 2.59 ( ) Any skin SAE 86 (.7%) 51 (.4%) 1.67 ( ) HPS2-THRIVE Collaborative Group. Eur Heart J. 213;34:
4 Effect of ERN/LRPT on Infection and Bleeding Serious Adverse Event ERN/LRPT Risk ratio (95% CI) (12,838) (12,835) Infection Lower respiratory 4.3% 3.7% 1.17 ( ) Urinary tract.9%.8% 1.7 ( ) Abdominal/gastrointestinal.6%.5% 1.26 ( ) Skin.5%.3% 1.66 ( ) Other 2.4% 1.7% 1.38 ( ) Any infection SAE (8.%) (6.6%) 1.22 ( ) Bleeding Gastrointestinal.8%.6% 1.53 ( ) Intracranial 1.1%.9% 1.17 ( ) Other.6%.4% 1.66 ( ) Any bleeding SAE 326 (2.5%) HPS2-THRIVE Collaborative Group. Eur Heart J. 213;34: (1.9%) 1.38 ( ) Effects of ER Niacin/Laropiprant on Lipids Year of Follow-Up LDL-C (mg/dl) HDL-C (mg/dl) Triglycerides (mg/dl) STUDY AVERAGE (mmol/l) (-.25) (.16) (-.37) Based on previous observational studies and randomized trials, it was anticipated such lipid differences might translate into a 1-15% reduction in vascular events HPS2-THRIVE Collaborative Group. Eur Heart J. 213;34: HPS2-THRIVE: Summary No significant benefit of ER niacin/laropiprant on the primary outcome of major vascular events when added to effective statin-based LDL-lowering therapy Significant excesses of serious adverse events (SAEs) due to known and unrecognised side-effects of niacin. Over 4 years, ER niacin/laropiprant led to SAEs in ~3 patients per 1 No clear evidence of differences in efficacy or safety in different types of patients (except for an excess of statin-related myopathy in Chinese patients) Findings are consistent with previous niacin trials The role of ER niacin for the treatment and prevention of cardiovascular disease needs to be reconsidered Fibric Acid Derivative Trials Helsinki Heart Study VA-HIT FIELD ACCORD HPS2-THRIVE Collaborative Group. Eur Heart J. 213;34: Helsinki Heart Study 4,81 men aged 4-55 years with non-hdl-c 2 mg/dl, initially free of coronary disease LDL-C 11%, HDL-C +11% 34% reduction in CHD endpoints Greatest benefits when triglyceride high or HDL-C low LDL-C/HDL-C >5. and triglycerides >2 mg/dl: risk was reduced by 71% Cumulative MIs+CV Deaths 1 1 % Gemfibrozil Years Veterans Affairs HDL Intervention Trial (VA-HIT) Gemfibrozil 6 mg bid 2,531 men with CAD HDL-C 4 (mean 32) LDL-C 14 (mean 111) Triglycerides 3 (mean 161) 25% diabetic 57% hypertensive BMI 29 kg/m 2 Followed for MI or coronary death over 5 years Frick MH, et al. N Engl J Med. 1987;317: Rubins HB, et al. N Engl J Med. 1999;341:
5 VA-HIT: Gemfibrozil vs. in Patients with Low HDL-C Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Design % change * P =.6 ** P <.1 No change -31% 6% -22%* -24%** LDL-C TG HDL-C Nonfatal Strokedeath MI or CHD Death 5-year study against a background of usual care, including the option to add other lipid-lowering therapies 9795 Type 2 Diabetes Patients No clear indication for lipidlowering therapy at baseline Fenofibrate 2 mg/day, n = Other lipid-lowering therapies, n = 49 +Other lipid-lowering therapies 5 Years or 5 CHD Events Rubins HB, et al. N Engl J Med. 1999;341: FIELD Study Investigators. Cardiovasc Diabetol. 24;3:9-24. FIELD: Baseline Characteristics Characteristic (n = 49) Fenofibrate (n = 4895) Male, % No Prior CVD, % Lipid parameters, mg/dl TC LDL-C HDL-C TG Dyslipidemic*, % *TG >15 mg/dl and HDL-C <4 mg/dl for men or <5 mg/dl for women FIELD: Primary and Secondary Endpoints Event Rate, % Fenofibrate 11% Reduction P =.16 24% Reduction 5.9 P = % Increase 4.2 P = % Reduction P =.35 CHD events* Nonfatal MI CHD Death Total CVD Coronary Events** Revascularization * Nonfatal MI and CHD death ** CHD events, stroke, CVD death, revascularizations % Reduction P = Keech A, et al. Lancet. 25;366: Keech A, et al. Lancet. 25;366: FIELD: Total CVD Events in Patient Subgroups ARR = 2.1% NNT = 48 14% Reduction P = Fenofibrate *<4 mg/dl (men) and <5 mg/dl (women) at baseline Triglycerides 15 mg/dl and low HDL-C at baseline Event Rate, % Patients With Low HDL-C* Patients With Dyslipidemia Keech A, et al. Lancet. 25;366: Event Rate, % 14% Reduction P = Fenofibrate ARR = 2.3% NNT = 44 Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Comparison of statin plus a fibrate vs statin monotherapy for reduction of CVD in diabetics at high CVD risk 5518 Type 2 Diabetes Patients Simvastatin + Fenofibrate Simvastatin + ACCORD Study Group. N Engl J Med. 21;362: Primary outcome : nonfatal MI, nonfatal stroke, or death from CV causes Follow-Up 4.7 Years
6 ACCORD Study Results Simvastatin + Fenofibrate ACCORD Study Group. N Engl J Med. 21;362: Simvastatin + Primary outcome 2.2% 2.4% NS (annual rate) Annual death rate 1.5% 1.6% NS Prespecified subgroup analysis suggested heterogeneity in treatment according to sex, with benefit for men and possible harm for women (P=.1 for interaction) P Possible benefit in fenofibrate group if baseline TG high >24 mg/dl and HDL-C <34 mg/dl. Primary outcome rate:12.4% fenofibrate vs. 17.3% placebo (P=.57 for interaction) ACCORD: Primary Outcome By Treatment Group and Baseline Subgroups Overall Fenofibrate % Events (# in group) 1.5% (2765) % Events (# in group) 11.3% (2753) Hazard Ratio Feno:Plac Interactio np Value Triglycerides & HDL.567 TG 24 mg/dl & HDL 34 mg/dl 12.4% (485) 17.3% (456) All others 1.X% (2264) 1.1% (2284) 1 2 Fenofibrate therapy better ACCORD Study Group. N Engl J Med. 21;362: therapy better Heart Protection Study (HPS): Major Vascular Events by Prior Disease Previous MI Other CHD (not MI) No prior CHD CVD PVD SIMVASTATIN PLACEBO (1269) (1267) 999 (23.5%) 125 (29.4%) 46 (18.9%) 591 (24.2%) 172 (18.7%) 212 (23.6%) Rate ratio & 95% CI STATIN better PLACEBO better 327 (24.7%) 42 (3.5%) Diabetes 276 (13.8%) 367 (18.6%) 24% SE 3 ALL PATIENTS 233 (19.8%) 2585 (25.2%) Heart Protection Study Collaborative Group. Lancet. 22;36:7-22. reduction (2P <.1) Treating to New Targets (TNT): Study Design Randomized, double-blind, placebo-controlled trial over 5 years 1,1 patients with: clinically evident CHD and LDL-C <13 mg/dl while on atorvastatin 1 mg daily LaRosa JC, et al. N Engl J Med. 25;352: Atorvastatin 8 mg Atorvastatin 1 mg Primary Endpoint: time to first major CV event* *CHD death, nonprocedural MI, resuscitation after cardiac arrest, or stroke TNT: Low LDL-C Benefits Patients With Diabetes and CHD Post hoc analysis: 15 subjects with diabetes, CHD, and LDL <13 mg/dl Atorvastatin 8 mg: 25% fewer CV events than in the 1-mg group Atorvastatin 1 mg: LDL=99 mg/dl Atorvastatin 8 mg: LDL=77 mg/dl Musculoskeletal safety profile comparable between 2 groups Lowering LDL levels below suggested guidelines continues to benefit high-risk patients Shepherd J, et al. Diabetes Care. 26 Jun;29(6): HPS: Vascular Events by LDL-C Baseline feature LDL-C < 1(2.6 mmol/l) < (3.4 mmol/l) STATIN PLACEBO Risk ratio & 95% CI (1269) (1267) STATIN better STATIN worse ALL PATIENTS (19.9%) (25.4%) Heart Protection Study Collaborative Group. Lancet. 22;36:7-22. Het c2 =.8 24% SE 2.6 reduction (2P<.1)
7 Case Study: Pat 62-year-old woman with family history of maternal uncle having MI at age 39 Physical exam normal except thickening of Achilles tendons bilaterally Labs Patient is euthyroid Chemistries: normal Total cholesterol: 35 mg/dl HDL-C: 5 mg/dl LDL-C: 21 mg/dl Triglycerides:175 mg/dl Genetic Etiologies for Very High LDL Familial Hypercholesterolemia (FH) LDL receptor mutation (heterozygous, homozygous, compound homozygous) Mutations in the gene for apo B can also give rise to FH (familial defective apo B). Deficiency of 7-alpha hydroxylase (cyp7a1mutation) Autosomal recessive hypercholesterolemia (due to reduced expression of adaptor protein that facilitates association of LDLR with clathrin in cell surface coated pits). Autosomal dominant hypercholesterolemia attributable to gain of function mutations in PCSK9 FH Prevalence Genetics Heterozygotes Frequency 1 in 3-5 One of most common congenital metabolic disorders Serum cholesterol: 3-55 mg/dl Since patients have one normal LDL-R gene, their hepatocytes take up LDL- C at approximately onehalf the rate of unaffected patients. Homozygotes Frequency 1 in 1 million Serum cholesterol: 65-1 mg/dl Have near total or total loss of LDL-R functionality Can inherit 2 copies of same mutant allele, or may be classified as compound homozygotes due to inheritance of 2 different mutant alleles Affected subjects are at increased risk for all forms of atherosclerotic disease and premature death secondary to lifelong pathogenic elevations in serum LDL-C. The gene for LDLR resides on the short arm of chromosome 19 (19p ). The Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff lists 1614 mutations in the LDL receptor gene. Goldberg AC, et al. J Clin Lipidol Jun;5(3 Suppl):S1-S8. Goldberg AC, et al. J Clin Lipidol Jun;5(3 Suppl):S1-S8. Physical Findings in Familial Hypercholesterolemia Yellow-orange cutaneous xanthomas Tendon xanthomas Xanthelasma Corneal arcus Heart murmur stemming from aortic stenosis Can develop supravalvular stenosis of the aorta Arterial bruits (carotid, femoral) arising from diffuse, systemic atherosclerosis Polyarthritis Tendinitis Screening for FH Adults ( 2 years) Children, adolescents and young adults (<2 years) Screening Recommendations LDL cholesterol 19 mg/dl or non-hdl cholesterol 22 mg/dl LDL cholesterol 16 mg/dl or non- HDL cholesterol 19 mg/dl. Ask about family history of high cholesterol and heart disease in first-degree relatives Higher likelihood of FH with positive family history of hypercholesterolemia or CHD onset < 55 years (men), < 65 years women Consider cholesterol screening starting at age 2 for children with a family history of premature CHD or elevated cholesterol All individuals should be screened by age 2 Goldberg AC, et al. J Clin Lipidol Jun;5(3 Suppl):S1-S8.
8 Treat All FH Patients Very high lifetime risk of coronary heart disease Very high risk of premature onset CHD Early and long term treatment is highly beneficial Long term drug therapy in patients with FH removes excess lifetime risk of CHD due to the genetic disorder, with a goal of reducing CHD risk to a level similar to that of the general population LDL apheresis: LDL>2 mg/dl; 13 mg/dl with Lp(a) >5-6 mg/dl Treat All FH Patients Untreated FH Mean onset CVD Men early 4 s Women in early 5 s 24 times higher risk of MI before age 4 Long-term statin treatment largely ameliorates excess CVD risk due to FH Risk of long-term statin treated FH patients = Risk of general population Goldberg AC, et al. J Clin Lipidol Jun;5(3 Suppl):S1-S8. Versmissen J, et al. BMJ. 28; 337: a2423 Aggressive Approaches to LDL Lowering and Novel agents ApoB (LDL-C, Non-HDL-C) Lowering LDL apheresis ApoB mrna antisense oligonucleotides (indicated for HoFH) Microsomal triglyceride transfer protein (MTP) inhibitors (indicated for HoFH) Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors Current Statins Maximize or optimize Ezetimibe Bile acid sequestrants Niacin Fibrates Future? ApoB formation inhibitors PCSK9 inhibitors MTP inhibitors HoFH=homozygous familial hypercholesterolemia Antisense Mechanism of Action An antisense oligonucleotide (ASO) blocks the mrna translation into protein, therefore blocking protein synthesis ApoB-1 as a target Essential for the synthesis and transport of VLDL and LDL-C Plays a crucial role in lipid management Reductions in LDL-C and Lp(a) Levels in Ho- FH (n=51) with Mipomersen Mean % change from baseline in LDL-C Mean (95% CI) % change from baseline in Lp(a) Reduction in LDL-C over 28 weeks Mipomersen 2 mg Reduction in Lp(a) over 28 weeks % 25% 8% 31% Raal FJ, et al. Lancet. 21:375(9719)
9 Mipomersen Safety Injection site reactions (84%), flu-like symptoms (3%), nausea, headache 8.4% of mipomersen-treated patients had ALT > 3x ULN on two consecutive measures 7 days apart (vs % for placebo) Reversible, median increase in hepatic fat with no effects noted on liver synthetic function (total bilirubin, PT, albumin) Hepatic steatosis is a risk factor for progressive liver disease Human Monoclonal Antibody to PCSK9* Changes in Apo B, Non-HDL-C, and Lipoprotein(a) from Baseline to Week 12 by Treatment Group Intervention % Change Apo B % Change Non-HDL-C % Change Lipoprotein(a) Alirocumab* 5 mg/2 weeks -27.3* -33.6* -13.3** Alirocumab 1 mg/2 weeks -48.1* -55.6* -26.1* Alirocumab 15 mg/2 weeks -56.1* -62.5* -28.6* Alirocumab 2 mg/4 weeks -28.7* -37.4* -6.7** Alirocumab 3 mg/4 weeks -33.1* -4.7* -7.9** * P<.1 for % change Alirocumab vs. placebo ** P =.5 for % change Alirocumab vs. placebo *Alirocumab is an investigational drug McKenney JM, et al. J Am Coll Cardiol. 212;59: Microsomal Transfer Protein Inhibitors Key Clinical Take Home Points Dose-escalation study in 6 patients with homozygous familial hypercholesterolemia Lomitapide,* 1 mg/kg daily, decreased LDL-C by 5.9% and Apo B by 55.6% from baseline Markedly reduces Apo-B production Adverse effects were elevated aminotransferase levels and hepatic fat accumulation in 1-4% of patients at the 1. mg/kg dose range *Lomitapide is only approved for use in patients with homozygous familial hypercholesterolemia. LDL-C remains the principle target of therapy for patients at risk for CAD. (Evidence Level A) The evidence for HDL-C raising/tg lowering providing additional benefit on top of statins to reduce CHD risk is disappointing. (FIELD, AIM HIGH, ACCORD) Non-HDL-C and ApoB are better predictors of CHD risk than LDL-C in patients with elevated TG. (Evidence Level A) We still need a trial of patients with high non-hdl-c who are at LDL-C targets to prove treatment benefit. Cuchel M, et al. N Engl J Med. 27;356: Getting Non-HDL to Target in Mixed Dyslipidemia Consider the patient: age, finances, side effects Intensify LDL-C lowering or use combination therapy to adjust HDL-C/TG TG level > 2 with LDL-C/HDL-C ratio >5? This patient will likely benefit from niacin or fibrate Follow NCEP guidelines, until trial evidence suggests differently! Conclusions: LDL, HDL, TG, non-hdl Benefit of adding niacin or fenofibrate to statin to raise HDL-C in patients with T2DM, mixed dyslipidemia and CAD? Clinical benefits of novel therapies to increase HDL-C? Last 2 decades focused on LDL lowering. Current evidence is lacking. Jury remains out. Next decade will likely focus on HDL-C, TG, non-hdl-c, Apo B, FBS, BP and obesity. In order to adequately reduce residual risk we will need to be more aggressive at treating all the risk factors for CHD and to develop systems to provide better treatment to large numbers of patients.
10 Conclusions: Familial Hypercholesterolemia FH is a common genetic disorder Diagnosis is critical not only for the patient but also for family members Cascade screening is mandatory Aggressive treatment of LDL is necessary Several new therapeutic agents are under development that will likely be effective for treatment of FH and statin-intolerant patients Questions?
Landmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More information2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Learning Objectives
Learning Objectives Utilize evidence-based lipoprotein management strategies for non-ldl-c lipid targets Describe the risk factors, disease spectrum, and appropriate management of familial hypercholesterolemia
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationAdvances in Lipid Management
Advances in Lipid Management Kavita Sharma, MD Assistant Professor of Medicine, Division of Cardiology Clinical Director of the Lipid Management Clinics, The Ohio State University Wexner Medical Center
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationFocus on FH (Familial Hypercholesterolemia) Joshua W. Knowles, MD PhD for PCNA May, 2013
Focus on FH (Familial Hypercholesterolemia) Joshua W. Knowles, MD PhD for PCNA May, 2013 Conflicts CMO for The FH Foundation Pre-talk quiz What is cascade screening? 1. screening all family members 2.
More informationDavid Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon
David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2063-8 Program Prior Authorization/Medical Necessity Medication Repatha (evolocumab) P&T Approval Date 5/2015, 9/2015, 11/2015,
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationCase Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic
Case Discussions: Treatment Strategies for High Risk Populations Peter H. Jones MD, FNLA Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Most Common Reasons for
More informationPCSK9 Inhibitors: Promise or Pitfall?
PCSK9 Inhibitors: Promise or Pitfall? Tracy Harlan, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics tracy harlan@uiowa.edu Tracy Harlan does not have any actual or potential
More informationManagement of LDL as a Risk Factor. Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil
Management of LDL as a Risk Factor Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Consulting for: Merck, Astra Zeneca, ISIS- Genzyme, Novo-Nordisk, BMS, Pfizer,
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationClinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date:
Clinical Policy: (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationDrug Class Monograph
Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016
More informationClinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPMN.184 Effective Date: 01/2017
Clinical Policy: (Repatha) Reference Number: ERX.SPMN.184 Effective Date: 01/2017 Last Review Date: Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More informationWhat Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment?
What Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment? Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director, Prevention Intervention Center University
More informationFamilial hypercholesterolaemia
Familial hypercholesterolaemia Jaimini Cegla MRCP FRCPath PhD Consultant in Chemical Pathology and Metabolic Medicine Hammersmith Hospital Lipid Clinic 20 April 2017 An unrecognised, potentially fatal,
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More information10/15/2012. Lessons Learned from Tim Russert: Investigating Residual Risk. Tim Russert: Residual CV Risk?
Lessons Learned from Tim Russert: Investigating Residual Risk Peter H. Jones, MD, FACP Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Houston, Texas Tim Russert:
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationHyperlipidemia and Cardiovascular Disease. Kathmandu November 2010 Harold E. Lebovitz, MD, FACE
Hyperlipidemia and Cardiovascular Disease Kathmandu November 21 Harold E. Lebovitz, MD, FACE Diabetes and Lifetime Risk for CHD Adjusted cummula ative incidence.7.6.5 Men 67% 3%.7.6.5 Women Diabetes No
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationNon-Statin Lipid-Lowering Agents M Holler - Last updated: 10/2016
Drug/Class Cholestyramine (Questran) Bile acid sequestrant Generic? Lipid Effects Y/N (monotherapy) Y LDL : 9% (4 g to 8 ; 21% (16 g to 20 ; 23% to 28% (>20 HDL : 4% to 8% (16 to 24 TG : 11% to 28% (4
More information4 th and Goal To Go How Low Should We Go? :
4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationProprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary
Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2062-8 Program Prior Authorization/Medical Necessity Medication Praluent (alirocumab) P&T Approval Date 5/2015, 8/2015, 9/2015,
More informationNovel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy
LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,
More informationDisclosures. Objectives 2/11/2017
Role of Non-Statin Therapy in CV Risk Reduction James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA,FASPC Clinical Assistant Professor of Medicine NYU School of Medicine NYU Langone Center for Cardiovascular
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Repatha) Reference Number: HIM.PA.SP46 Effective Date: 01.01.18 Last Review Date: Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this
More informationPCSK9 Agents Drug Class Prior Authorization Protocol
PCSK9 Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationNew ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?
New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate
More informationCase Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk
Case Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk Kim K. Birtcher, PharmD, MS, AACC Clinical Professor University of Houston College of Pharmacy Houston,
More informationJuxtapid (lomitapide)
Juxtapid (lomitapide) Policy Number: 5.01.599 Last Review: 06/2018 Origination: 07/2015 Next Review: 06/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Juxtapid
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Proprotein Convertase Subtilisin/kexin type 9 Page 1 of 24 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Proprotein Convertase Subtilisin/kexin type 9 (PCSK9)
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationManagement of Lipids Beyond Statin Therapy
Management of Lipids Beyond Statin Therapy Jessica L. Kerr, PharmD, CDE Associate Professor SIUE School of Pharmacy Jared Sheley, PharmD, BCPS Clinical Assistant Professor SIUE School of Pharmacy Disclosures/Conflict
More informationCholesterol Medicines New & Old: What to Use When
Cholesterol Medicines New & Old: What to Use When Patrick E. McBride, M.D., M.P.H. Division of Cardiovascular Medicine Preventive Cardiology Program Disclosures McBride no conflicts of interest Outline
More informationREPATHA (PCSK9 INHIBITORS)
REPATHA (PCSK9 INHIBITS) Indications: PCSK9 Inhibitors are indicated for treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease as
More informationWhat do the guidelines say about combination therapy?
What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationDecline in CV-Mortality
Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer
More informationClinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPA.169 Effective Date:
Clinical Policy: (Repatha) Reference Number: ERX.SPA.169 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationNovel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane
Novel HDL Targeted Therapies: The Search Continues Assoc. Prof. K.Kostner,, Univ. of Qld, Brisbane Kostner, 2007 2008 LDL Target depends on your level of Risk Acute Plaque Rupture ACS (UA/NSTEMI/STEMI)
More informationPharmacy Management Drug Policy
SUBJECT: ; Praluent (alirocumab), Repatha (evolocumab) POLICY NUMBER: Pharmacy-61 EFFECTIVE DATE: 8/15 LAST REVIEW DATE: 9/22/2017 If the member s subscriber contract excludes coverage for a specific service
More informationFamilial Hypercholeterolaemia
Familial Hypercholeterolaemia Is it all about statins? Gerald F Watts DSc PhD MD FRACP FRCP Professor and Head, Cardiometabolic Service, Department of Cardiology, Royal Perth Hospital School of Medicine,
More informationA New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies
A New Age of Dyslipidemia Treatment: Role of Non- Statin Therapies BRODY MAACK, PHARMD, BCACP, CTTS Objectives 1. Review current guidelines regarding use of statin medications in the treatment and prevention
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationProspective Natural-History Study of Coronary Atherosclerosis
Introduction Review of literature from April 2010 to present Concentrated on clinical studies Categories: Atherosclerosis, Lipids, Diabetes and CVD Risk Medical Therapy Statins really could there be anything
More informationLipid Management: A Case-Based Approach. Overview. Simple Lipid Therapy Approach. Patients have lipid disorders of:
Lipid Management: A Case-Based Approach Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public
More informationClinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPA.171 Effective Date:
Clinical Policy: (Kynamro) Reference Number: ERX.SPA.171 Effective Date: 01.11.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationClinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPMN.186 Effective Date: 01/2017
Clinical Policy: (Kynamro) Reference Number: ERX.SPMN.186 Effective Date: 01/2017 Last Review Date: Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.
More informationYoung high risk patients the role of statins Dr. Mohamed Jeilan
Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationEvolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors
Evolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina at Chapel Hill
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationDrug Prior Authorization Guideline PCSK9 Inhibitors -
Drug Prior Authorization Guideline PCSK9 Inhibitors - REPATHA (evolocumab) PRALUENT (alirocumab) PA9911 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes-as shown below Additional
More informationNew Drugs for Lipid Management
New Drugs for Lipid Management John Larry, MD Assistant Professor-Clinical Section Chief, OSU East Cardiovascular Medicine Department of Internal Medicine Division of Cardiovascular Medicine The Ohio State
More informationNew Drugs for Lipid Management
New Drugs for Lipid Management John Larry, MD Assistant Professor-Clinical Section Chief, OSU East Cardiovascular Medicine Department of Internal Medicine Division of Cardiovascular Medicine The Ohio State
More informationSubject: Repatha (evolocumab) Original Effective Date: 09/28/2015. Policy Number: MCP-258 Revision Date(s): 5/4/16; 4/17/17
Subject: Repatha (evolocumab) Original Effective Date: 09/28/2015 Policy Number: MCP-258 Revision Date(s): 5/4/16; 4/17/17 Review Date(s): 5/4/2016, 4/17/2017, 7/10/2018 DISCLAIMER This Medical Policy
More informationGet a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management
Get a Statin or Not? Treatment Strategies in Dyslipidemia Management Michelle Chu, PharmD, BCACP, CDE Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Sahar Dagher, PharmD Virtual Care
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
More informationDIAGNOSIS AND TREATMENT OF FH CHILDREN. O. GUARDAMAGNA Dipartimento di Scienze della Sanità Pubblica e Pediatriche UNIVERSITA DI TORINO
DIAGNOSIS AND TREATMENT OF FH CHILDREN O. GUARDAMAGNA Dipartimento di Scienze della Sanità Pubblica e Pediatriche UNIVERSITA DI TORINO DISCLOSURES Kowa MSD Pfizer Astrazeneca Synageva/Alexion OUTLINE Background
More informationUPDATES IN LIPID MANAGEMENT
UPDATES IN LIPID 2017 Cardiovascular Symposium MANAGEMENT SUDHA RAVILLA, MD, DIPLOMATE, ABCL MEDICAL DIRECTOR CLINICAL LIPIDOLOGY TMHPP METABOLIC HEALTH CENTER INTRODUCTION CVD is STILL the No. 1 cause
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationADMINISTRATIVE POLICY AND PROCEDURE
ADMINISTRATIVE POLICY PROCEDURE Policy #: Subject: PCSK9 INHIBITS (ex: Repatha) Section: Care Management Effective Date: January 1, 2015 Revision Date(s): NA Review Date(s): NA Responsible Parties: Patryce
More informationLipids & Hypertension Update
Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationLipid Control Today: Management within the Context of other Cardiovascular Risk Factors
Best Practices Lipid Control Today: Management within the Context of other Cardiovascular Risk Factors James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC Lipidology & Cardiovascular Disease Prevention
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More information2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice
2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice Nattawut Wongpraparut, MD, FACP, FACC, FSCAI Associate Professor of Medicine, Division of Cardiology, Department of Medicine
More informationImproving Complex Risk Assessment and Diagnosis of Patients with Severe Dyslipidemia
Improving Complex Risk Assessment and Diagnosis of Patients with Severe Dyslipidemia April 3, 213 Anaheim, California Educational Partner: Session 1: Improving Complex Risk Assessment and Diagnosis of
More informationPCSK9 Inhibitors Praluent (Alirocumab) and Repatha (Evolocumab) For the Treatment of Familial Hypercholesterolemia
PCSK9 Inhibitors Praluent (Alirocumab) and Repatha (Evolocumab) For the Treatment of Familial Hypercholesterolemia Policy Number: Original Effective Date: MM.04.037 08/01/2016 Line(s) of Business: HMO;
More informationGuidelines on Lowering LDL-C Levels
Scientific Insights Into LDL-C, PCSK9, and CV Risks High circulating LDL-C levels are associated with increased risk for ASCVD 1,2 Statin drugs interfere with cholesterol production, lowering serum LDL-C
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationManaging Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus
Managing Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA Chair, ACC Prevention of Cardiovascular Disease Council and Section The Medical University
More informationThe Target is LDL, HDL not so much
The Target is LDL, HDL not so much HDL: A riddle wrapped in a mystery inside an enigma Jacques Genest MD Cardiovascular Research Laboratories McGill University Health Center Disclosure J. Genest MD 2013
More informationESC, ACC/AHA and Malaysian CPG Guidelines on lipids Statins Introduction to non-statins Guideline recommendations for non-statins Clinical trials of
ESC, ACC/AHA and Malaysian CPG Guidelines on lipids Statins Introduction to non-statins Guideline recommendations for non-statins Clinical trials of non-statin drugs Non-statin vs placebo Non-statin vs
More informationCholesterol Treatment Update
Cholesterol Treatment Update Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public Health Disclosure:
More informationLow-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationNicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist
1 Nicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist New Cardiovascular Horizons Multidisciplinary Strategies for Optimal Cardiovascular Care February 7, 2015 2 Objectives After participating in
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationEffect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, CM Ballantyne, R Somaratne, J Legg, SM Wasserman, R Scott, MJ Koren, and EA Stein for
More information